Clinical Trials Directory

Trials / Unknown

UnknownNCT03059784

APP-based Multifaceted Management After PCI

Mobile Application-based Multifaceted Management to Improve Long-term Care After Percutaneous Coronary Intervention

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
1,100 (estimated)
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

High rates of recurrent cardiovascular events and readmission after percutaneous coronary intervention (PCI) are important issues. Guidelines emphasize rehabilitation and secondary prevention. But many patients are lack of effective management after PCI.This study is aimed to examine the effect of mobile application (APP)-based multifaceted management on the improvement of long-term care after PCI.

Detailed description

This is a cluster-randomized controlled trial to evaluate the effect of APP-based multifaceted management strategy on improvement of long-term care for medication adherence,risk factor control, and reduction of adverse events, readmission rate and mortality after PCI.It includes knowledge education, medication reminder,advice provision, support to change lifestyle behaviors. The program is interactive between care provider and patients. A total of 20 wards will be randomly assigned to intervention or usual care.Anticipated 1100 patients after PCI will be participated in the trial. All the participants will be followed up until 12 months.

Conditions

Interventions

TypeNameDescription
OTHERAPP-based multifaceted managementPatients after PCI will be regularly given education materials, medication reminders, life-style behaviors instruction through APP. Cardiologists can interact with patients on advice provision and clinical support after discharge through APP.

Timeline

Start date
2017-03-01
Primary completion
2018-07-01
Completion
2018-08-01
First posted
2017-02-23
Last updated
2017-02-23

Source: ClinicalTrials.gov record NCT03059784. Inclusion in this directory is not an endorsement.